Because EGFR is known to activate NF-κB through a PKC-dependent mechanism, the research group led by Xin Lin sought to investigate whether a CARMA3-containing CBM signaling complex might serve to bridge EGFR stimulation and NF-κB activation in cancer cells. Here, CARD10 is linked to cancer.